The RemeGen Difference
Dr. Fang received his Ph.D degree from Dalhousie University, Canada, and completed post-doctoral training at Harvard Medical School. He has extensive experience in biologics research and development from his work spanning both in industrial and academic settings. Dr. Fang is a professor at Tongji University in Shanghai. Dr. Fang is the founder of RemeGen and, since its inception, has been serving as the CEO and CSO of this company.
Dr. Fang has published articles in Nature Biotechnology, PNAS, Cancer Research, and other international academic journals. He holds more than 40 patents and a number of molecules he invented are currently in clinical trials. Dr. Fang is also the inventor of conbercept, the first ophthalmic biologic commercialized in China.
Additionally, Dr. Fang serves as an expert advisor for the National 1000 Talents Plan and is part of the Shandong Taishan Scholar Group. He is also part of the advisory team for the 12th 5-Year Plan Panel and the 13th 5-Year Plan Panel of the National Major New Drug Creation in China.
As a globally-minded Chinese pharmaceutical company, RemeGen is already a pioneer—and our manufacturing practices are no different. We are happy usher in a new era of pharmaceutical manufacturing in China, knowing that it will allow us to develop and manufacture the highest quality medicines that open new therapeutic possibilities for patients that are in great need of something new and better.
Unhindered by costs and other difficulties common in China, our new, state-of-the-art manufacturing facility—which has a capacity of six 2,000L disposable bioreactors—was built to specifically comply with US, EU, and Chinese regulations. Here, we are poised to successfully meet the demands of a global economy that is faced to solve some of the largest health problems of the 21st century.
If you would like additional information on partnering with RemeGen, please contact our business development lead,